Health Care & Life Sciences » Pharmaceuticals | Innovus Pharmaceuticals Inc.

Innovus Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
33.40
7.50
55.90
829.90
1,564.90
1,248
Total Accounts Receivable
216.60
191.60
83.10
33.60
68.30
818
Inventories
177.90
266.00
254.40
599.90
1,850.60
2,621
Other Current Assets
56.50
55.00
53.30
863.70
238.20
329
Total Current Assets
484.30
520.10
446.70
2,327.00
3,721.90
5,016
Net Property, Plant & Equipment
79.00
54.50
35.10
29.60
62.50
247
Intangible Assets
1,528.20
1,484.60
5,850.20
5,855.80
5,225.70
4,843
Other Assets
21.90
21.90
15.00
15.00
20.90
21
Total Assets
2,113.40
2,081.10
6,347.00
8,227.40
9,030.90
10,127
ST Debt & Current Portion LT Debt
370.00
314.00
1,102.50
1,340.80
1,304.70
Accounts Payable
143.80
362.20
155.50
1,210.10
2,305.90
Other Current Liabilities
574.50
77.80
1,373.60
1,480.20
1,535.10
Total Current Liabilities
1,088.20
754.00
2,631.60
4,031.10
5,145.60
Long-Term Debt
511.50
521.90
25.00
54.50
-
Provision for Risks & Charges
-
324.40
3,229.80
1,515.90
-
Other Liabilities
366.10
906.90
906.90
1,531.90
2,982.30
Total Liabilities
1,965.80
2,507.10
6,793.30
7,133.40
8,128.00
Common Equity (Total)
147.70
426.00
446.30
1,094.00
902.90
Total Shareholders' Equity
147.70
426.00
446.30
1,094.00
902.90
Total Equity
147.70
426.00
446.30
1,094.00
902.90
Liabilities & Shareholders' Equity
2,113.40
2,081.10
6,347.00
8,227.40
9,030.90

About Innovus Pharmaceuticals

View Profile
Address
8845 Rehco Road
San Diego California 92122
United States
Employees -
Website http://www.innovuspharma.com
Updated 07/08/2019
Innovus Pharmaceuticals, Inc. engages in the commercialization, licensing, and development of non-prescription medicine, and consumer care products for health and vitality, and respiratory diseases. It also provides packaged healthcare solutions through over-the-counter, medicines and consumer and health products, which it market directly or through commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through on-line channels, retailers and wholesalers. The company business model leverages the ability to acquire and in-license commercial products that are supported by scientific, and or clinical evidence, place them through it existing supply chain, retail and on-line channels.